Clinical Trials and Novel Therapies Safety and Tolerability of Miransertib (MK-7075) in Participants with PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Enrolled in Other Studies (MK-7075-006)
Description
This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum (PROS) or Proteus Syndrome (PS). This is an extension of other miransertib studies (MK-7075-002 [NCT03094832] or ArQule CU/EAP [NCT03317366]), and may also enroll participants who are approved for MK-7075-002 but have not yet started miransertib therapy.
Eligibility
- Ages 2 to 120 years
- Diagnosed with PROS or Proteus Syndrome
- Previously or currently enrolled in a miransertib study
Detailed inclusion and exclusion criteria are listed at clinicaltrials.gov.
